Lilly webcast on late-stage tirzepatide program in T2D November 20
Eli Lilly (NYSE:LLY) will host a webcast on Friday, November 20, at 11:00 am ET to provide an overview of its tirzepatide Phase 3 program in type 2 diabetes (T2D). The presentation will address trial designs and expected timing of data readouts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.